Glypican-3 Targeted Human Heavy Chain Antibody as a Drug Carrier for Hepatocellular Carcinoma Therapy
Hirofumi Hanaoka(Kansai Medical University), Hisataka Kobayashi(National Cancer Institute), Kazuhide Sato(SHOWA Medical University), Yuko Nakamura(University of Tsukuba), Mingqian Feng(Huazhong Agricultural University), In‐Sook Kim(Frederick National Laboratory for Cancer Research), Mitchell Ho(National Institutes of Health), Chang H. Paik, Yen Phung(National Institutes of Health), Rira Watanabe(National Cancer Institute), Tadanobu Nagaya(National Institutes of Health), Toshiko Harada(National Cancer Institute), Peter L. Choyke(National Cancer Institute), Wei Gao(Fujian Medical University)
Cited by 72
Related Papers
Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas
|Nature Genetics|1997|1.5k
Differential regulation of bile acid homeostasis by the farnesoid X receptor in liver and intestine
|Journal of Lipid Research|2007|595
Spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice
|Carcinogenesis|2006|359
Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma
|JAMA Oncology|2015|309
DYRK1A-mediated Hyperphosphorylation of Tau
|Journal of Biological Chemistry|2007|273